Camrelizumab
- Generic Name
- Camrelizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1798286-48-2
- Unique Ingredient Identifier
- 73096E137E
- Background
Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
- Indication
⑴用于至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤患者的治疗。
⑵用于霍奇金淋巴瘤（三线）、肝细胞癌（二线）、非鳞状非小细胞肺癌（一线联合）、食管鳞癌（二线）。
⑶用于既往接受过二线及以上化疗后疾病进展或不可耐受的晚期鼻咽癌患者的治疗。
⑷联合顺铂和吉西他滨用于局部复发或转移性鼻咽癌患者的一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-10-28
- Last Posted Date
- 2023-03-23
- Lead Sponsor
- Wei Jiang
- Target Recruit Count
- 200
- Registration Number
- NCT05097209
- Locations
- 🇨🇳
Wuzhou Red Cross Hospital, Wuzhou, Guangxi, China
🇨🇳Guangxi Nanxishan hospital, Guilin, Guangxi, China
🇨🇳Guilin Medical University, Guilin, Guangxi, China
Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer
- First Posted Date
- 2021-10-27
- Last Posted Date
- 2021-10-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 102
- Registration Number
- NCT05095636
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 30
- Registration Number
- NCT05093140
Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-10-21
- Last Posted Date
- 2021-10-21
- Lead Sponsor
- Aiping Shi
- Target Recruit Count
- 30
- Registration Number
- NCT05088057
- Locations
- 🇨🇳
Aiping Shi, Changchun, Jilin, China
DCF Combined With Camrelizumab in the Treatment of Esophageal Cancer
- First Posted Date
- 2021-09-21
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 55
- Registration Number
- NCT05050760
- Locations
- 🇨🇳
Xijing Hospital, Xi'an, Shaanxi, China
To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma
- First Posted Date
- 2021-09-21
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Target Recruit Count
- 60
- Registration Number
- NCT05051865
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- Feng Wang
- Target Recruit Count
- 234
- Registration Number
- NCT05049681
Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.
- Conditions
- Interventions
- First Posted Date
- 2021-09-14
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Zhigang Li
- Target Recruit Count
- 426
- Registration Number
- NCT05043688
- Locations
- 🇨🇳
Anyang Tumour Hospital, Anyang, China
🇨🇳Sun yat-sen University Cancer Center, Guangzhou, China
🇨🇳Anhui Provincial Hospital, Hefei, China
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 450
- Registration Number
- NCT05042375
- Locations
- 🇨🇳
Shaoyang Central Hospital, Shaoyang, Hunan, China
🇨🇳Xiangyang Central Hospital, Xiangyang, Hubei, China
🇨🇳Hunan Cancer Hospital-Thoracic Medicine Department I, Changsha, Hunan, China
Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2022-05-19
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT05019534
- Locations
- 🇨🇳
Sichuan University West China Hospital, Chengdu, Sichuan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.